Literature DB >> 27779247

HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients.

M Frías1, D Rodríguez-Cano1, F Cuenca-López1, J Macías2, A Gordon1, B Manzanares-Martín3, J A Pineda2, Á Camacho1, J Torre-Cisneros1, J Peña3, A Rivero-Juárez1, A Rivero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27779247     DOI： 10.1038/tpj.2016.80

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


× No keyword cloud information.
  6 in total

1.  Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.

Authors:  Yao-Chun Hsu; Jaw-Town Lin; Hsiu J Ho; Yu-Hsi Kao; Yen-Tsung Huang; Nai-Wan Hsiao; Ming-Shiang Wu; Yi-Ya Liu; Chun-Ying Wu
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

2.  Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.

Authors:  P Labarga; J V Fernandez-Montero; P Barreiro; J Pinilla; E Vispo; C de Mendoza; Z Plaza; V Soriano
Journal:  J Viral Hepat       Date:  2013-10-06       Impact factor: 3.728

3.  HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.

Authors:  M Frías; D Rodríguez-Cano; F Cuenca-López; J Macías; A Gordon; B Manzanares-Martín; J A Pineda; Á Camacho; J Torre-Cisneros; J Peña; A Rivero-Juárez; A Rivero
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

4.  Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.

Authors:  Juan Berenguer; Francisco X Zamora; Ana Carrero; Miguel A Von Wichmann; Manel Crespo; José López-Aldeguer; Teresa Aldámiz-Echevarría; Marisa Montes; Carmen Quereda; María J Téllez; María J Galindo; José Sanz; Ignacio Santos; Josep M Guardiola; Herminia Esteban; José M Bellón; Juan González-García
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

5.  Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

Authors:  Alessio Aghemo; Gian Maria Prati; Maria Grazia Rumi; Roberta Soffredini; Roberta D'Ambrosio; Emanuela Orsi; Stella De Nicola; Elisabetta Degasperi; Valeria Grancini; Massimo Colombo
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

6.  The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

Authors:  Salvador Vergara; Juan Macías; Antonio Rivero; Alicia Gutiérrez-Valencia; Mercedes González-Serrano; Dolores Merino; Ma José Ríos; José Angel García-García; Angela Camacho; Luis López-Cortés; Josefa Ruiz; Julián de la Torre; Pompeyo Viciana; Juan A Pineda
Journal:  Clin Infect Dis       Date:  2007-09-11       Impact factor: 9.079
  6 in total
  1 in total

1.  Detecting serum and urine metabolic profile changes of CCl4-liver fibrosis in rats at 12 weeks based on gas chromatography-mass spectrometry.

Authors:  Jiarong Gao; Xiu-Juan Qin; Hui Jiang; Jin-Feng Chen; Ting Wang; Ting Zhang; Shuang-Zhi Xu; Jun-Mei Song
Journal:  Exp Ther Med       Date:  2017-06-26       Impact factor: 2.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.